Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome
The BEtaferon®/BEtaseron® in Newly Emerging MS For Initial Treatment (BENEFIT) trial assessed the efficacy of early versus delayed treatment with interferon beta-1b for patients with clinically isolated syndrome (CIS). Patients were randomly assigned to receive either interferon beta-1b 250 μg every...
Main Author: | Mark S. Freedman |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2014-11-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285614549554 |
Similar Items
-
Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials
by: Yamaguchi Takuhiro, et al.
Published: (2011-05-01) -
Review of the clinical evidence for interferon β 1a (Rebif®) in the treatment of multiple sclerosis
by: Francesco Manfredonia, et al.
Published: (2008-04-01) -
Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment
by: Afsaneh Shirani, et al.
Published: (2015-01-01) -
The clinical and pharmacogenomic determinants of interferon beta induced liver injury in multiple sclerosis
by: Kowalec, Kaarina
Published: (2016) -
Beta-interferons in multiple sclerosis
by: Aggarwal Sourabh, et al.
Published: (2010-01-01)